Thanks to Spinraza and biosims—if not aducanumb—Biogen CEO Vounatsos scored $18M+ in 2019 pay

Between a huge Alzheimer’s drug setback last spring, its resurrection in the fall and a COVID-19 “superspreader” meeting early this year, Biogen has routinely made big headlines—and obviously, they weren't always positive.

Still, steering the ship through it all delivered CEO Michel Vounatsos a hefty raise to more than $18 million in pay last year.